Drug Approval | May 10, 2024
Alembic Pharmaceuticals receives 5 USFDA product approvals in Q1 FY25
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
ORACEA is a trademark of Galderma Holdings, S.A.
Wipro's MPPP360 platform will assist Independent Health in streamlining the payment process to seamlessly integrate these new provisions
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Colchicine Capsules are indicated for prophylaxis of gout flares in adult
Subscribe To Our Newsletter & Stay Updated
